
Opinion|Videos|October 16, 2024 (Updated: October 16, 2024)
Depression Treatment: Expert Guide to Medication Management & Therapeutic Success
Experts in the management of depression provide insights into understanding medication mechanisms, assessing when treatments are effective, and navigating therapy adjustments to optimize outcomes and complement various MOAs
Advertisement
Episodes in this series

Advertisement
Related to this article

Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.

Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.

Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.

Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.

Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.

The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.

Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Shelves Fast-Track Drug Review Initiative
2
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
3
Scams: What Psychiatrists Need to Know
4
Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and Schizophrenia
5

